MOESM1 of Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Additional file 1 Kaplan-Meier estimates of a progression-free survival (PFS) and b overall survival (OS) in the first-line subgroup according to programmed death-ligand 1 (PD-L1) status (based on expression in ≥1% of tumor cells). CI confidence interval, NE not evaluable. Kaplan-Meier estimates of progression-free survival and overall survival for patients in the first-line subgroup according to programmed death-ligand 1 status.